Limits...
Topical Mitomycin-C versus Subconjunctival 5-Fluorouracil for Management of Bleb Failure.

Pakravan M, Miraftabi A, Yazdani S, Koohestani N, Yaseri M - J Ophthalmic Vis Res (2011)

Bottom Line: Complete success was defined as 5 < IOP ≤ 18 mmHg without medications.Mean preoperative IOP was 20.5±8.85 mmHg in the MMC group and 25.82±11.35 mmHg in the 5-FU group (P = 0.129), which was decreased to 13.2±6.1 and 10.6±4.8 mmHg respectively after 12 months (P = 0.159).Topical MMC 0.02% drops are more convenient and can be initiated first, while 5-FU injections may be reserved for eyes with an insufficient response to topical MMC.

View Article: PubMed Central - PubMed

Affiliation: Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ABSTRACT

Purpose: To compare the efficacy and safety of topical mitomycin-C (MMC) drops with that of subconjunctival 5-fluorouracil (5-FU) injections for management of early bleb failure after trabeculectomy or combined phacoemulsification and trabeculectomy with posterior chamber intraocular lens implantation (PT+PCIOL).

Methods: In a randomized comparative study, 37 eyes of 37 patients with impending early bleb failure received MMC 0.02% eye drops for 2 or 4 weeks (19 eyes) or subconjunctival 5-FU injections, 5 mg per dose (18 eyes). Complete success was defined as 5 < IOP ≤ 18 mmHg without medications.

Results: Baseline characteristics were comparable between the study groups. However, there were more cases of combined PT+PCIOL in the MMC group [11 (57.9%) eyes versus 3 (16.7%) eyes, P = 0.017]. Mean preoperative IOP was 20.5±8.85 mmHg in the MMC group and 25.82±11.35 mmHg in the 5-FU group (P = 0.129), which was decreased to 13.2±6.1 and 10.6±4.8 mmHg respectively after 12 months (P = 0.159). There was no significant difference between the study groups in terms of bleb extent (P = 0.170), height (P = 0.178) or vascularity (P = 0.366). At the end of the study, complete success was achieved in 13 eyes (68.4%) in the MMC group and 14 eyes (77.8%) in the 5-FU group (P = 0.714). The survival of success at 8 months (median follow-up) was 89.5% and 86.5% in the MMC and 5-FU groups respectively; the number of glaucoma medications (P = 0.707) and best-corrected visual acuity (P = 0.550) were also comparable. Complication rates were similar in the study groups (P = 0.140).

Conclusion: Topical MMC 0.02% has comparable safety and efficacy to subconjunctival 5-FU injections for management of early bleb failure. Topical MMC 0.02% drops are more convenient and can be initiated first, while 5-FU injections may be reserved for eyes with an insufficient response to topical MMC.

No MeSH data available.


Related in: MedlinePlus

Changes in bleb vascularity from baseline in the MMC and 5-FU groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC3306090&req=5

f2-jovr-6-2-078: Changes in bleb vascularity from baseline in the MMC and 5-FU groups.

Mentions: Intraocular pressure was significantly reduced from baseline in both study groups at 1 and 2 weeks and 1, 3, 6, and 12 months (all P-values ≤ 0.01). No significant difference was observed between the study groups in terms of IOP at any interval (all P-values > 0.25) (Table 2 and Fig. 1). There were no significant differences in bleb height and extent between the two groups (bleb extent: P = 0.170, height: P = 0.178, vascularity: P = 0.366). In the MMC group there was a borderline decrease in bleb vascularity after one week (P = 0.05), and a significant decrease after two weeks, and one and three months (P < 0.05 for all comparisons). Bleb vascularity was decreased significantly in the 5-FU group after one and two weeks, and at one and three months (P < 0.05 for all comparisons; Fig. 2). The study groups were comparable in terms of bleb morphology up to 3 months after intervention (P = 0.380; Fig. 3).


Topical Mitomycin-C versus Subconjunctival 5-Fluorouracil for Management of Bleb Failure.

Pakravan M, Miraftabi A, Yazdani S, Koohestani N, Yaseri M - J Ophthalmic Vis Res (2011)

Changes in bleb vascularity from baseline in the MMC and 5-FU groups.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC3306090&req=5

f2-jovr-6-2-078: Changes in bleb vascularity from baseline in the MMC and 5-FU groups.
Mentions: Intraocular pressure was significantly reduced from baseline in both study groups at 1 and 2 weeks and 1, 3, 6, and 12 months (all P-values ≤ 0.01). No significant difference was observed between the study groups in terms of IOP at any interval (all P-values > 0.25) (Table 2 and Fig. 1). There were no significant differences in bleb height and extent between the two groups (bleb extent: P = 0.170, height: P = 0.178, vascularity: P = 0.366). In the MMC group there was a borderline decrease in bleb vascularity after one week (P = 0.05), and a significant decrease after two weeks, and one and three months (P < 0.05 for all comparisons). Bleb vascularity was decreased significantly in the 5-FU group after one and two weeks, and at one and three months (P < 0.05 for all comparisons; Fig. 2). The study groups were comparable in terms of bleb morphology up to 3 months after intervention (P = 0.380; Fig. 3).

Bottom Line: Complete success was defined as 5 < IOP ≤ 18 mmHg without medications.Mean preoperative IOP was 20.5±8.85 mmHg in the MMC group and 25.82±11.35 mmHg in the 5-FU group (P = 0.129), which was decreased to 13.2±6.1 and 10.6±4.8 mmHg respectively after 12 months (P = 0.159).Topical MMC 0.02% drops are more convenient and can be initiated first, while 5-FU injections may be reserved for eyes with an insufficient response to topical MMC.

View Article: PubMed Central - PubMed

Affiliation: Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

ABSTRACT

Purpose: To compare the efficacy and safety of topical mitomycin-C (MMC) drops with that of subconjunctival 5-fluorouracil (5-FU) injections for management of early bleb failure after trabeculectomy or combined phacoemulsification and trabeculectomy with posterior chamber intraocular lens implantation (PT+PCIOL).

Methods: In a randomized comparative study, 37 eyes of 37 patients with impending early bleb failure received MMC 0.02% eye drops for 2 or 4 weeks (19 eyes) or subconjunctival 5-FU injections, 5 mg per dose (18 eyes). Complete success was defined as 5 < IOP ≤ 18 mmHg without medications.

Results: Baseline characteristics were comparable between the study groups. However, there were more cases of combined PT+PCIOL in the MMC group [11 (57.9%) eyes versus 3 (16.7%) eyes, P = 0.017]. Mean preoperative IOP was 20.5±8.85 mmHg in the MMC group and 25.82±11.35 mmHg in the 5-FU group (P = 0.129), which was decreased to 13.2±6.1 and 10.6±4.8 mmHg respectively after 12 months (P = 0.159). There was no significant difference between the study groups in terms of bleb extent (P = 0.170), height (P = 0.178) or vascularity (P = 0.366). At the end of the study, complete success was achieved in 13 eyes (68.4%) in the MMC group and 14 eyes (77.8%) in the 5-FU group (P = 0.714). The survival of success at 8 months (median follow-up) was 89.5% and 86.5% in the MMC and 5-FU groups respectively; the number of glaucoma medications (P = 0.707) and best-corrected visual acuity (P = 0.550) were also comparable. Complication rates were similar in the study groups (P = 0.140).

Conclusion: Topical MMC 0.02% has comparable safety and efficacy to subconjunctival 5-FU injections for management of early bleb failure. Topical MMC 0.02% drops are more convenient and can be initiated first, while 5-FU injections may be reserved for eyes with an insufficient response to topical MMC.

No MeSH data available.


Related in: MedlinePlus